ACON logo

ACLARION INC

ACONNASDAQ
πŸ† #5044 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track ACON
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$4M
Small Cap
πŸ“ˆRevenue Growth (YoY)
33.1%
High Growth
πŸ“ŠGross Margin
21.8%
Moderate
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
42.1x
Expensive
Otter Score
β€”
Insufficient data
No chart data available for ACON.

Trading Snapshot

Day Range
β€”
52-Week Range
$1.33 – $9.36
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
2.9M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$75,730
Last Q Revenue
$33,733
P/E Ratio
β€”
P/S Ratio
42.1x
EPS (TTM)
$-7.92
Dividend Yield
β€”
Dilution (1yr)
+41400.5%
ACON logo

ACLARION INC

ACON
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$76Kβ–² +65.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-291.3%β–² +58.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$7Mβ–² +27.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$7Mβ–² +28.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
532Kβ–² +41400.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$12Mβ–² +$12M YoY
StockOtter Β· stockotter.space

About ACLARION INC

Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.